Drug
Ser 252
Ser 252: highest development phase Phase 1, developed by Serina Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Serina Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SER-252 (PEOZ-apomorphine) NCT07422675 | Phase 1 | PARKINSON DISEASE (Disorder) |
Latest
No recent events.
Follow Ser 252 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.